Table 1 International research-based pharmaceutical cases in India [[3]]
From: “To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
Company | Drug | Issue | Now |
|---|---|---|---|
Bayer | Nexavar (kidney cancer) | Patent office ordered Bayer to license its drug to an Indian firm to produce low-cost generics | IPAB rejected Bayer’s appeal to overturn compulsory license on Mar 4, 2013; Bayer to now appeal decision to Mumbai High Court |
Bayer | Nexavar (kidney cancer) | Sued Cipla, an Indian firm, for patent infringement | Hearing in Dec 2012 |
Novartis | Glivec (leukaemia) | India refused to grant Swiss firm a patent in 2006 | Indian Supreme Court rejected Novartis’ patent plea on April 1, 2013 after 7-year battle |
Roche | Tarceva (cancer) | Sued Indian companies for infringing its patent | Delhi High Court dismissed Roche’s patent infringement suit in Sept 2012 after 4-year struggle |
Roche | Valcyte (AIDS) | Patent office revoked Roche’s patent | Appeal pending to IPAB* |
Gilead | Viread (HIV) | Patent office rejected two patents | Appealed; the case is still pending |